Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome
- 28 Downloads
To evaluate role of AMH as a diagnostic tool for PCOS.
This was a prospective case–control study on women attending Gynae OPD of Dr RML Hospital, New Delhi, from 1 November 2015 to 31 March 2017. Study comprised of 45 women with PCOS, diagnosed using Rotterdam criteria and 45 women as controls. Clinical history included oligomenorrhea, hirsutism, examination included BMI, Ferriman–Gallwey score, investigations included blood for FSH, LH, estradiol, TSH, prolactin, total testosterone, AMH level and pelvic USG which was done for all women.
Both PCOS cases and control were matched for age and BMI. Median AMH levels of 4.32 ng/ml in PCOS cases was almost twice that of 2.32 ng/ml in controls (p = 0.001). Maximum diagnostic potential of AMH alone for PCOS was at a cut-off of 3.44 ng/ml with sensitivity of 77.78% and specificity of 68.89%. AMH was used as an adjunct to existing Rotterdam criteria as the fourth parameter OA+HA+PCOM+AMH (any three out of four) yielded sensitivity of 80%. However, when PCOM in Rotterdam criteria was replaced by AMH, OA+HA+AMH (any two out of three) or OA/HA+AMH resulted in sensitivity of 86.67 and 71.11%, respectively.
AMH levels were significantly higher in PCOS than in controls. AMH as an independent marker could not effectively diagnose PCOS. However, AMH levels as an adjunct to existing Rotterdam criteria for diagnosis of PCOS had good diagnostic potential.
KeywordsPCOS AMH Rotterdam criteria Hyperandrogenism (HA) Oligomenorrhea (OA) Polycystic ovarian morphology (PCOM)
We thank all the patients who consented to participate in this study.
Compliance with Ethical Standards
Conflict of interest
All the authors declare that they have no relevant conflict of interest.
The study was approved by Medical Ethical committee of PGIMER & DR RML Hospital, New Delhi.
Informed consent was taken from all the patients who agreed to participate in the study.
- 21.Tayrab E, Ali M, Modawe G, et al. Serum Anti-Müllerian hormone as laboratory predictor in infertile women with and without polycystic ovary syndrome. Am J Res Com. 2014;2(3):61–6.Google Scholar